Orchestra BioMed Director Increases Stake: 5,760 Shares Acquired

Rhea-AI Filing Summary

Eric S. Fain, a director of Orchestra BioMed Holdings, Inc. (OBIO), reported an acquisition of 5,760 shares of the company's common stock at a weighted-average price of $2.61 per share. Following this transaction the reporting person beneficially owns 71,709 shares indirectly through the Fain Living Trust. The filing identifies the purchase as multiple transactions aggregated to a weighted-average price and notes the reporting person is filing individually as a director. No derivative transactions, dispositions, or other changes in ownership are reported in this Form 4.

Positive

• Director purchase recorded: Reporting person acquired 5,760 shares of common stock, indicating a board member increased exposure to the company's equity.
• Clear price disclosure: Weighted-average price reported as $2.61 with a disclosed purchase range of $2.60 to $2.61, providing transparency about execution prices.
• Beneficial ownership disclosed: Total beneficial ownership of 71,709 shares is stated and identified as held indirectly via the Fain Living Trust.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director added 5,760 shares at a $2.61 weighted-average price, modestly increasing indirect ownership to 71,709 shares.

The acquisition is a straightforward open-market purchase reported on Form 4. The filing shows only non-derivative shares were acquired and the shares are held indirectly via a trust. Because the report lists a weighted-average price and states purchases occurred at $2.60 to $2.61, it appears the transactions were executed over multiple trades at nearly identical prices. The disclosure does not include any sales, option exercises, or additional derivative instruments.

Corporate Governance Expert

TL;DR: A company director increased indirect shareholdings via a trust by 5,760 common shares, now totaling 71,709 beneficially owned shares.

This Form 4 is limited to a non-derivative purchase and confirms the reporting relationship as a director and that ownership is indirect through the Fain Living Trust. The form includes an explanatory footnote about the weighted-average price range. There are no disclosures here about any changes to board roles, pledging of shares, or plan-based transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fain Eric S

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/25/2025		P		5,760	A	$2.61(1)	71,709	I	By the Fain Living Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.60 to $2.61. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

	/s/ Andrew Taylor, Attorney-in-Fact	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did OBIO director Eric S. Fain purchase according to the Form 4?

The reporting person acquired 5,760 shares of Orchestra BioMed Holdings, Inc. common stock as a non-derivative purchase.

At what price were the OBIO shares purchased?

The reported weighted-average price was $2.61 per share, with purchases executed in the range of $2.60 to $2.61.

How many OBIO shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owns 71,709 shares indirectly through the Fain Living Trust.

What is the reporting person's relationship to OBIO?

The Form 4 identifies the reporting person, Eric S. Fain, as a director of Orchestra BioMed Holdings, Inc.

Were any derivative securities or dispositions reported in this Form 4?

No derivative securities or dispositions are reported; the Form 4 lists only the non-derivative purchase.